Advertisement
"We are grateful for David's many contributions to Cardiokine, whichinclude building the current development team, successfully completing a $50million Series B financing and most recently, securing a global co-developmentand commercialization agreement for Lixivaptan with Biogen Idec. We wish himcontinued success in the future," said James H. Cavanaugh, Ph.D., Chairman ofCardiokine's Board of Directors.
Advertisement
The Cardiokine Board is expected to make an announcement shortly regardingMr. Brand's successor.
Mr. Brand was recently appointed to the Board of Directors of InteKrinTherapeutics, Inc., a privately held biopharmaceutical company pursuing theclinical development of therapeutics for diabetes, obesity and metabolicdisorders. He has more than 30 years of global pharmaceutical experience inproduct development, acquisitions, marketing and operational management withGlaxoSmithKline ("GSK") and its predecessor companies. Mr. Brand joined GSKInternational in 1983 in the post of Vice PresidentCardiovascular/Gastrointestinal Marketing. Over the next seven years, he heldsenior marketing, business development/acquisitions and operational positionsin Europe, Asia and Latin America.
In 1990, Mr. Brand joined the U.S. GSK organization and was appointedBusiness Unit Head for Gastrointestinal and Central Nervous System Products,where he led the launch activities for Paxil(R) and Kytril(R). In 1994, asVice President, New Product Development, he was responsible for the pre-launchplanning for Coreg(R), Hycamtin(R), Requip(R) and numerous in-licensing andco-promotion partnerships. From 1997 through 2003, he was responsible for theAnti-infective, Metabolic and Cardiovascular Business Units that launched theRequip and Avandia(R) franchise and developed Augmentin(R) ES/XR.
Mr. Brand joined Cardiokine as President and CEO in July 2004.
About Cardiokine
Cardiokine, headquartered in Philadelphia, is a privately held specialtypharmaceutical company focused on the development of pharmaceuticals for thetreatment and prevention of heart failure and related cardiovascular andmetabolic indications. Additional information about Cardiokine is availableat www.cardiokine.com.Contacts: Corporate: Media: Federica O'Brien, Chief Financial Officer Barbara Lindheim Cardiokine, Inc. GendeLLindheim BioCom (215) 399-1200 Partners (212) 918-4650
SOURCE Cardiokine, Inc.
